Table 1 Sociodemographic, clinical and psychological characteristics of the study sample (n = 3347)
n | % | |
|---|---|---|
Sociodemographic factors | ||
Age at survey (years) M = 78.1, SD = 6.3 | ||
≤ 70 | 375 | 11.2 |
> 70 ≤ 80 | 1599 | 47.8 |
> 80 | 1373 | 41.0 |
Educational level | ||
primary, secondary - low | 1187 | 39.8 |
secondary - intermediate | 519 | 17.4 |
secondary - high | 362 | 12.2 |
tertiary | 911 | 30.6 |
Partnership | ||
yes | 3053 | 92.1 |
no | 260 | 7.9 |
Children | ||
0 | 376 | 11.5 |
≥ 1 | 2901 | 88.5 |
Clinical characteristics | ||
Age at surgery (years) M = 62.5, SD = 6.1 | ||
≤ 55 | 399 | 11.9 |
> 55 ≤ 65 | 1742 | 52.1 |
> 65 | 1206 | 36.0 |
Time since surgery (years) M = 15.6, SD = 3.8 | ||
≤ 10 | 198 | 5.9 |
> 10 ≤ 15 | 1425 | 42.6 |
> 15 ≤ 20 | 1349 | 40.3 |
> 20 | 375 | 11.2 |
Second primary cancer | ||
yes | 430 | 12.9 |
no | 2917 | 87.1 |
Family history of PCa | ||
yes | 1297 | 38.8 |
no | 2050 | 61.2 |
PSA level at diagnosis (ng/ml) | ||
≤ 4 | 307 | 9.9 |
> 4 ≤ 10 | 1870 | 60.1 |
> 10 | 934 | 30.0 |
Gleason score | ||
2–6 | 1424 | 50.5 |
7, 3 + 4 = 7, 4 + 3 = 7 | 1131 | 40.0 |
8–10 | 269 | 9.5 |
Grading | ||
G I | 133 | 4.1 |
G II | 2292 | 70.3 |
G III | 833 | 25.6 |
Organ-confined stage at RP | ||
yes | 2343 | 71.0 |
no | 955 | 29.0 |
Biochemical recurrence during follow-up | ||
yes | 1211 | 40.9 |
no | 1749 | 59.1 |
Biochemical recurrence at survey | ||
yes | 572 | 20.0 |
no | 2295 | 80.0 |
Discontinued PSA follow-up | ||
yes | 186 | 5.6 |
no | 3161 | 94.4 |
Ongoing treatment at survey | ||
yes | 423 | 12.9 |
no | 2864 | 87.1 |
Psychosocial factors | ||
PHQ-2 (depression screening) | ||
positive screening (≥3) | 469 | 14.8 |
negative screening (< 3) | 2707 | 85.2 |
GAD-2 (anxiety disorder screening) | ||
positive screening (≥3) | 360 | 11.4 |
negative screening (< 3) | 2798 | 88.6 |
Perceived severity of disease | ||
low | 1448 | 45.0 |
high | 1770 | 55.0 |
Well-being | ||
low | 1075 | 34.2 |
high | 2067 | 65.8 |
Benefit Finding | ||
low | 1823 | 56.0 |
high | 1429 | 44.0 |